You are here:

midazolam (Epistatus)

Advice

following an abbreviated submission:

midazolam (Epistatus®) is accepted for use within NHS Scotland.

Indication under review: treatment of prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years.

The availability of midazolam (Epistatus) provides a licensed alternative to a previously available unlicensed preparation (10mg/mL).

Drug Details

Drug Name: midazolam (Epistatus)
SMC Drug ID: 1279/17
Manufacturer: Special Products Ltd
Indication: Treatment of prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years.
BNF Category:
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 13 November 2017

Back